



(51) International Patent Classification:

C07K 7/64 (2006.01) *C07K 14/47* (2006.01)
A61P 31/10 (2006.01) *A61K 38/00* (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2021/039129

(22) International Filing Date:

25 June 2021 (25.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/044,943 26 June 2020 (26.06.2020) US


(71) Applicant: **THE UNIVERSITY OF SOUTHERN CALIFORNIA** [US/US]; USC Stevens Center for Innovation, 1150 S. Olive Street, Suite 2300, Los Angeles, California 90015 (US).

(72) Inventors: **SELSTED, Michael E.**; 810 N. Chester Ave., Pasadena, California 91104 (US). **TRAN, Dat Q.**; 2912 West Hellman Avenue, Alhambra, California 91803 (US). **SCHAAL, Justin B.**; 215 S. Orange Street, Orange, California 92866 (US). **BASSO, Virginia**; 521 S Lark Ellen Avenue, West Covina, California 91791 (US).

(74) Agent: **BRILLHART, Kurt** et al.; FISH IP LAW, LLP, 2603 Main Street, Suite 1000, Irvine, California 92614 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF FUNGAL INFECTIONS

**FIG. 16**

(57) Abstract: Peptide analogs of a θ -defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These θ -defensin analogs are protective at concentrations where naturally occurring θ -defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ -defensins.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*